Background: Percutaneous left ventricular transapical access (TA) can be utilized for a multitude of diagnostic and interventional procedures in structural heart disease (SHD) . With advancements in imaging and device technology, applicability of this approach is expanding. We present our growing experience in utilizing TA for structural heart interventions. Methods: We evaluated patients at our center, from April 2008 to June 2013, who presented for SHD intervention. Ninety four TA were performed in 80 consecutive patients (54 males, 71AE30 years) with 4 patients having double TA during the same intervention and 10 patients having repeat TA during subsequent SHD interventions (double TA n¼13). Since August 2010, computed tomographic angiography (CTA)/ fluoroscopy fusion imaging (HeartNavigator, Philips, Netherlands) has been used to guide TA puncture. Results: All TA were successfully performed for the following interventions: 74 mitral paravalvular leak (PVL) closure, 6 aortic PVL closure, 14 left ventricular pseudoaneurysm (LVPA) closure, 2 ventricular septal defect closure, 8 mitral transcatheter valve-in-valve implantations, and 10 combined procedures. Average initial/ final sheath sizes were 6F and 7F (range 5F-12F). TA was closed using an Amplatzer Ductal Occluder n¼86, Amplatzer Vascular Plug II n¼3, Muscular VSD Occluder n¼3, and coils n¼2. Complications occurred in 13 cases (14%): hemothorax n¼5, pericardial effusion/tamponade n¼1; persistent access site bleeding requiring surgical closure n¼2, non-fatal device migration n¼3 (2 ventricular, 1 epicardial requiring surgical closure), and death n¼2. One death occurred in a patient with suprasystemic pulmonary hypertension developing pulseless electrical activity and one death occurred after PVL closure in the setting of untreated critical aortic stenosis and epicardial device migration. There was no significant difference in complications associated with use of fusion imaging (with 10% vs without 17.6%, p¼0.29). Conclusions: TA is useful in multiple SHD interventions. Despite fusion imaging, complications still occur. More reliable TA closure devices may further improve the safety and generalizabilty of this approach for more complex SHD interventions.
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Background: Patients with a patent foramen ovale (PFO) and a history of paradoxical embolism are at risk to suffer from recurrent events even if the PFO was closed percutaneously. This study investigated the long-term results of a high-volume center. Methods: PFOs were closed in patients with a history of at least one assumed paradoxical embolism (TIA, stroke or peripheral embolism) or a diving accident. The type of closure device was chosen due to availability and operator's decision. All patients were prescribed a dual antiplatelet therapy (aspirin and clopidogrel) for the first 6 months after the procedure. Echocardiographic studies were performed at 4 weeks and 6 months after the index procedure. Patients were evaluated for residual shunts and the incidence of potential adverse events. All patients were followed annually through office visits, questionnaires and phone calls, or by contacting the referring physicians. Results: Between August 1998 and December 2012 percutaneous closure of patent foramen ovale was performed in 2831 patients. The mean age of patients was 50 AE 13 years. 55% were male (n¼1551). Indication for PFO-closure was a history of migraine (n¼481), peripheral embolism (n¼55), diving accident (n¼36) or cryptogenic cerebral ischemia (TIA in n¼1334 or stroke in n¼1666). 563 patients (19.9%) suffered from recurrent neurological events before percutaneous PFO-closure. We used 23 different types of closure devices. The most commonly used occluders were the Amplatzer (n¼914), the Helex (n¼470), the Premere (n¼409) and the CardioSEAL-STARflex device (n¼303). Within a total of 8,873 patient years of follow-up (mean follow-up duration: 38 months), there were 89 recurrent embolic events. This compares to an annual event rate of 1.0%. 29 patients suffered from recurrent TIA, and in 54 patients an ischemic strokes occurred. In 6 patients peripheral embolic events occurred. In 122 patients (4.3%) a second device implantation was performed to close a residual shunt.
Conclusions:
The results of this study represent the clinical experience of a European high-volume center in PFO-closure and show a favorable and much lower annual recurrent event rate compared to previously published randomized trials.
TCT-100
Effect 
